Harvest Time? Medicago And GSK Expect Summer Readout For Plant-Based COVID Vaccine

Vaccine Grown In Greenhouse Crops

Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.

Medicago factory, North Carolina
Medicago currently only has enough capacity to supply Canada's 76 million dose order, but wants to eventually produce 1 billion doses a year. • Source: Medicago

Medicago and its partner GlaxoSmithKline could be on track to have a Phase III readout for their COVID-19 vaccine candidate by summer, which the Canadian company hopes would also demonstrate the efficacy of its plant-based vaccine platform.

Its approach is unlike any other COVID-19 vaccine developer: its proprietary technology uses the Australian tobacco plant N benthamiana as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip